TCGA-HQ-A2OF-01A-11R-A26T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 63.96189225
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.430
- G2M_CHECKPOINT+0.420
- E2F_TARGETS+0.400
- MYC_TARGETS_V1+0.360
- MITOTIC_SPINDLE+0.320
- MYC_TARGETS_V2+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.290
- BILE_ACID_METABOLISM+0.250
- ANDROGEN_RESPONSE+0.240
- PEROXISOME+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- TNFA_SIGNALING_VIA_NFKB-0.450
- ANGIOGENESIS-0.400
- INFLAMMATORY_RESPONSE-0.400
- IL6_JAK_STAT3_SIGNALING-0.380
- IL2_STAT5_SIGNALING-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5d396a37-9b3d-4255-a3bd-f4a7c9480aee | — | — | 0.925 |
| 2 | TCGA-ZF-A9RM-01A-11R-A38B-07 | — | — | 0.875 |
| 3 | 13649cf2-1dc4-408f-9063-31a2b9bb7157 | — | — | 0.874 |
| 4 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.873 |
| 5 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.870 |
| 6 | DRR168570 | — | — | 0.870 |
| 7 | TCGA-OR-A5LE-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.856 |
| 8 | SRR1313100 | — | B | 0.854 |
| 9 | MDT-AP-2956 | Med | Medulloblastoma | 0.854 |
| 10 | 236350e9-8964-42ae-8880-d2f2281ff993 | — | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.120 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |